HPV16L1 capsid protein expressed from viable adenovirus recombinants elicits neutralizing antibody in mice

被引：7

作者：

Berg, Michael

Garnbhira, Ratish

Siracusa, Mark

Hoiczyk, Egbert

Roden, Richard

Ketner, Gary

机构：

[1] Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA

[2] Johns Hopkins Sch Med, Dept Pathol, Baltimore, MD 21205 USA

来源：

VACCINE | 2007年 / 25卷 / 17期

关键词：

recombinant adenovirus vaccine; HPV; immunogenicity;

D O I：

10.1016/j.vaccine.2006.06.080

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Immunization against human papillomavirus (HPV) infection promises to reduce the worldwide burden of cervical cancer. To evaluate the potential of live recombinant adenoviruses for induction of HPV infection-blocking immunity, we prepared viable adenovirus recombinants that express the HPV16 L1 gene from the adenovirus major late transcriptional unit. Adenovirus-produced HPV16 L1 assembles into virus-like particles (VLPs) in infected cells in culture. Purified HPV 16 VLPs are recognized by HPV 16 neutralizing antibodies and induce high neutralizing titers when injected intraperitoneally into mice. Canine oral papillomavirus VLPs derived from previously described recombinants also induce strong antibody responses in mice. These data support our suggestion that viable adenovirus recombinants will be able to induce protective immunity to papillomavirus infection during replication in human vaccinees. (c) 2006 Elsevier Ltd. All rights reserved.

引用

页码：3501 / 3510

页数：10

共 32 条

[1]

[Anonymous], 2001, Anal Biochem

[2] Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1 [J].

Baud, D ;

Ponci, F ;

Bobst, M ;

De Grandi, P ;

Nardelli-Haefliger, D .

JOURNAL OF VIROLOGY, 2004, 78 (23) :12901-12909

[3] Viable adenovirus vaccine prototypes: High-level production of a papillomavirus capsid antigen from the major late transcriptional unit [J].

Berg, M ;

DiFatta, J ;

Hoiczyk, E ;

Schlegel, R ;

Ketner, G .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (12) :4590-4595

[4]

Bosch F Xavier, 2003, J Natl Cancer Inst Monogr, P3

[5] The causal relation between human papillomavirus and cervical cancer [J].

Bosch, FX ;

Lorincz, A ;

Muñoz, N ;

Meijer, CJLM ;

Shah, KV .

JOURNAL OF CLINICAL PATHOLOGY, 2002, 55 (04) :244-265

[6] IMMUNIZATION WITH VIRUS-LIKE PARTICLES FROM COTTONTAIL RABBIT PAPILLOMAVIRUS (CRPV) CAN PROTECT AGAINST EXPERIMENTAL CRPV INFECTION [J].

BREITBURD, F ;

KIRNBAUER, R ;

HUBBERT, NL ;

NONNENMACHER, B ;

TRINDINHDESMARQUET, C ;

ORTH, G ;

SCHILLER, JT ;

LOWY, DR .

JOURNAL OF VIROLOGY, 1995, 69 (06) :3959-3963

[7] RESTRICTED CHANGES IN THE ADENOVIRUS DNA-BINDING PROTEIN THAT LEAD TO EXTENDED HOST RANGE OR TEMPERATURE-SENSITIVE PHENOTYPES [J].

BROUGH, DE ;

RICE, SA ;

SELL, S ;

KLESSIG, DF .

JOURNAL OF VIROLOGY, 1985, 55 (01) :206-212

[8] Efficient intracellular assembly of papillomaviral vectors [J].

Buck, CB ;

Pastrana, DV ;

Lowy, DR ;

Schiller, JT .

JOURNAL OF VIROLOGY, 2004, 78 (02) :751-757

[9] An adenovirus simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge [J].

Buge, SL ;

Richardson, E ;

Alipanah, S ;

Markham, P ;

Cheng, S ;

Kalyan, N ;

Miller, CJ ;

Lubeck, M ;

Udem, S ;

Eldridge, J ;

RobertGuroff, M .

JOURNAL OF VIROLOGY, 1997, 71 (11) :8531-8541

[10] Specific inactivation of inhibitory sequences in the 5′ end of the human papillomavirus type 16 L1 open reading frame results in production of high levels of L1 protein in human epithelial cells [J].

Collier, B ;

Öberg, D ;

Zhao, XM ;

Schwartz, S .

JOURNAL OF VIROLOGY, 2002, 76 (06) :2739-2752

← 1 2 3 4 →